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IT’S TIME FOR A NEW LOW-DOSE-RADIATION RISK ASSESSMENT 
PARADIGM—ONE THAT ACKNOWLEDGES HORMESIS
Bobby R. Scott, PhD h Lovelace Respiratory Research Institute
h The current system of radiation protection for humans is based on the linear-no-
threshold (LNT) risk-assessment paradigm. Perceived harm to irradiated nuclear workers
and the public is mainly reflected through calculated hypothetical increased cancers. The
LNT-based system of protection employs easy-to-implement measures of radiation expo-
sure. Such measures include the equivalent dose (a biological-damage-potential-weighted
measure) and the effective dose (equivalent dose multiplied by a tissue-specific relative
sensitivity factor for stochastic effects). These weighted doses have special units such as the
sievert (Sv) and millisievert (mSv, one thousandth of a sievert). Radiation-induced harm
is controlled via enforcing exposure limits expressed as effective dose. Expected cancer
cases can be easily computed based on the summed effective dose (person-sievert) for an
irradiated group or population. Yet the current system of radiation protection needs revi-
sion because radiation-induced natural protection (hormesis) has been neglected. A
novel, nonlinear, hormetic relative risk model for radiation-induced cancers is discussed
in the context of establishing new radiation exposure limits for nuclear workers and the
public.
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INTRODUCTION
The current system of limiting human exposure to ionizing radiation
is based on the premise that the risk of deleterious stochastic effects such
as cancer increases as a linear-no-threshold (LNT) function of the
absorbed radiation dose (i.e., radiation energy deposited in tissue divided
by the tissue mass). This is known as the LNT hypothesis and has no sci-
entific basis. The linearly increasing risk function is also often called the
LNT model. Such a linear relationship, if correct, means that doubling the
radiation dose doubles the risk of harm. Conversely, reducing the dose
one million-fold is supposed to reduce the risk by the same factor.
Some basic terminology is explained below to facilitate following the
later sections of this paper. 
High- and Low-LET Radiations
Two types of radiation (high and low linear energy transfer [LET])
are usually distinguished in characterizing radiation risks to humans.
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High-LET forms include alpha particles, neutrons, and heavy ions that
produce intense ionization patterns when interacting with biological tis-
sue. Considerable energy is deposited when traversing a narrow thickness
of tissue. Low-LET forms include x and gamma rays and beta particles
that deposit far less energy when traversing a narrow thickness of tissue.
Units for Expressing Radiation Doses
Radiation dose is expressed in different ways depending on the
intended usage. A fundamental unit is the absorbed radiation dose,
which is a measure of energy deposited in tissue (or other material) divid-
ed by the mass irradiated. Typical units of absorbed dose are the gray
(Gy) which is equal to 1 joule/kg, and the milligray (mGy), which is one
thousandth of a gray. These units can be applied when characterizing any
type of radiobiological damage.
For regulating radiation exposure of humans (e.g., setting radiation
exposure limits) and for low-dose risk assessment, special radiation dose
units have been established that are based on the linear-no-threshold
[LNT] hypothesis. These units are the result of applying statistical
weights called radiation weighting factors (WR) to radiation-specific doses
and are expressed in units such as the sieverts (Sv) and millisieverts
(mSv). These weighted doses are called equivalent doses and can be added
for a given tissue. To account for differing sensitivities of different tissue,
a second set of weights called tissue weighting factors (WT) are employed to
the equivalent doses. The resulting weighted doses can also be added and
the resultant dose is called effective dose and expressed in sieverts or mil-
lisieverts. Under presumed LNT dose-response functions for all cancer
types, the effective dose represents the uniform gamma-ray dose to the
total body that would incur the same overall cancer risk as is associated
with the person’s actual exposure, irrespective of its nonuniformity and
irrespective of the type and energies of the radiations that are involved. 
Radiation Dose Limits
Human radiation exposures are limited for nuclear workers, the pub-
lic, and other groups based on limiting the effective dose. For example,
the effective dose limit for nuclear workers is 50 mSv/y and for the pub-
lic is 1 mSv/y based on U.S. Department of Energy and Nuclear
Regulatory Commission regulatory policies (Metting 2005). The U.S.
Environmental Protection Agency’s regulatory policy limits on release of
radioactivity to air is based on limiting the effective dose to humans to 0.1
mSv/y, and for public drinking water the corresponding limit is 0.04
mSv/y. For a point of reference, natural background radiation doses in
the United States are associated with an effective dose of about 3 mSv/y
(radon exposure included) (Metting 2005). For Ramsar, Iran, the corre-
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sponding dose associated with natural background radiation is about 200
mSv/y. Interestingly, such high background radiation doses appear to be
associated with radiation hormesis-related protection against cancer
(Frigèrio and Stowe 1976; Nambi and Soman 1987), i.e., a reduction in
cancers.
Low Dose/Dose Rate Cancer Risk Assessment within the LNT Framework
Under the LNT risk assessment framework, effective doses for indi-
viduals can be added to obtained person-sievert (a collective dose) for
population exposure, and the collective dose can be used to calculate the
expected number of cancers among an irradiated population. Similarly,
effective dose can be used to assign an individual specific cancer risk.
However, low doses are often delivered at low rates and a correction is
made for a reduction in harm after low-rate exposure as compared to
high-rate exposure. For low doses and dose rates, a low-dose and dose-
rate effectiveness factor (DDREF) is used to reduce the slope of the can-
cer risk curve by a fixed amount, usually a factor of 2 (Mitchel 2006).
However with the LNT framework, reducing the effective dose by a factor
of 2 has the same effect. By using the LNT-based DDREF approach for low-
dose, low-dose-rate risk assessment, one essentially dismisses the possibil-
ity of radiation-induced protective effects (hormesis), as the dose-
response curve slope is constrained to be positive. 
Hormetic Dose-Response Curves
With hormesis, low doses of radiation protect against cancer, leading
to a negative slope in the low-dose region for the dose-response curve.
High doses, however, inhibit protection causing risk to then increase as
dose increases. This yields what has often been called a U- or J-shaped
dose-response curve (Calabrese and Baldwin 2001; Calabrese 2004, 2005;
Calabrese et al. 2006). 
DIFFERENT CLASSES OF RADIATION-ASSOCIATED HORMESIS
This paper distinguishes three classes of radiation hormesis based on
the recent recommendations of Calabrese et al. (2007):
1. Radiation conditioning hormesis: This form of hormesis relates to circum-
stances where a small radiation dose (mild stress) or moderate dose ad-
ministered as a low rate (prolonged mild stress) activates protective
processes that in turn suppress harm from a subsequent damaging large
radiation dose. 
2. Radiation hormesis: A small radiation dose (mild stress) or a moderate
dose given at a low rate (recurring mild stresses) activates protective
processes and reduces the level of biological harm to below the spon-
taneous level.
New low-dose-radiation risk assessment paradigm
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3. Radiation post-exposure conditioning hormesis: Damage normally caused by
a large radiation dose or large dose of some other agent is reduced as a
result of a subsequent exposure to a small radiation dose (mild stress)
or a moderate dose delivered at a low rate (repeated mild stresses).
Sheldon Wolff’s group (Olivieri et al. 1984; Wolff 1989, 1996) were the
first to demonstrate and publish radiation conditioning hormesis data.
When human lymphocytes were cultured with tritiated thymidine, which
was a source of low-level chronic beta radiation, and then briefly exposed
to 1500 mGy of x rays, the yield of chromatid aberrations from the x-ray
exposure was suppressed. In a 1988 publication (Wolff et al. 1988) by his
group, it was also demonstrated that human lymphocytes exposed to low
doses of ionizing radiation (mild stress) became refractory to chemical
mutagens that induced double-strand breaks in DNA. Howard Ducoff
(1975) was the first to demonstrate radiation hormesis in insects. This
author benefited greatly by participating in some of Dr. Ducoff’s research
as a graduate student at the University of Illinois. Members of this
research group are now known as the Irradiating Illini. 
T.D. Luckey, in his 1991 book entitled Radiation Hormesis, reported
extensive data on the indicated topic, including data showing that repeat-
ed mild stresses associated with chronic low-rate exposure (involving low-
LET radiation or low- plus high-LET radiation) significantly reduced the
cancer incidence or mortality to below the level for spontaneously occur-
ring cancers. Recently, such chronic radiation hormesis has been demon-
strated for lung cancer in a very large number of epidemiological and
ecological studies (Sanders and Scott 2007).
Ullrich et al. (1976) were the first to demonstrate a pronounced radi-
ation hormesis effect (for lung cancer) in gamma-ray irradiated female
RFM mice. The mice had a high spontaneous frequency of cancer implicat-
ing high genomic instability burdens. The pronounced radiation horme-
sis effect was similar in magnitude to the radiation hormesis demonstrat-
ed for neoplastic transformation by Azzam et al. (1996) for mouse embryo
fibroblast cells exposed to x rays in vitro. Further, dose-response curves for
neoplastic transformation were remarkably similar to those reported by
Ullrich et al. (1976) for lung cancer. Just as in the Ullrich et al. study with
high spontaneous lung cancer, there was a high spontaneous frequency of
transformations for the mouse embryo fibroblasts, implicating a high
genomic instability burden for the unirradiated cells. Such hormetic
observations now are thought to relate to a dependency of protective
intercellular signaling on the concentration of cells bearing genomic
instability (Bauer 1996, 2000; Portess et al. 2007; Scott 2007a,b,c).
Protective signaling intensity for protective apoptotic pathways is thought
to increase with increasing numbers of genomically unstable cells (Scott
2004; Scott et al. 2007), i.e., a form of natural protection. The distribution
B. R. Scott
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of mild radiation hits among the target cell population appears also to be
an important determinant of the protective signaling intensity (Bond et
al. 1987; Feinendegen et al. 2004; Rithidech and Scott 2007), including
signaling related to induced immunity (Laster et al. 2007). 
Ullrich and Storer (1979) apparently attributed the radiation-horme-
sis-like observation for lung cancer in mice to systematic errors in lung
cancer detection based on the methodology used. However, such a sys-
tematic error should operate at all dose levels, including those for the
controls; and thus correcting such an error would not be expected to
eradicate the hormetic dose-response curve shape. This can be demon-
strated by assigning an arbitrary large systematic error (e.g., 50%) to each
dose group including the controls and correcting the data. When evalu-
ating relative risk, the correction is canceled so the hormetic curve shape
remains. In addition, the study by Ullrich et al. (1976) not only demon-
strated radiation hormesis for lung cancer, but it was also demonstrated
for reticulum cell sarcoma for both gamma-ray and neutron exposures.
Edouard Azzam (Azzam et al. 1996) and colleagues were the first to
demonstrate radiation hormesis in vitro by exposing mouse embryo
fibroblasts in culture to low doses of x-rays. Their findings were later con-
firmed by Redpath et al. (2001, 2003). Studies by Dr. Redpath’s group also
demonstrated the importance of the type of radiation as well as dose rate
in radiation hormesis response (Redpath et al. 2001, 2003; Ko et al. 2004,
Elmore et al. 2005; Redpath and Elmore 2007). At the encouragement of
this author, Day et al. (2007) performed the first studies demonstrating
radiation post-exposure conditioning hormesis in mice (prostate gland).
Chromosomal inversions associated with a large radiation dose were com-
pletely prevented by a subsequent small radiation dose (mild stress). Now
there are many publications related to the indicated classes of radiation-
associated hormesis (e.g., Liu et al. 1987, 1994; Hosoi and Sakamoto 1993;
Cohen 1995; Howe 1995; Khokhryakov et al. 1996; Wolff 1996; Jaworowski
1997, 2001; Rossi and Zaider 1997; Hashimoto et al. 1999; Tokarskaya et
al. 1995, 1997, 2002; Redpath et al. 2001, 2003; Nyström et al. 2002; Wei
and Sugahara 2002; Liu 2003, 2004, 2007; Mitchel et al. 2003; Pollycove
and Feinendegen 2003; Sakai et al. 2003; Chen et al. 2004, Feinendegen et
al. 2004; Hooker et al. 2004; Ko et al. 2004; Mitchel 2004, 2005, 2006, 2007;
Scott 2004, 2005a,b, 2007a,b,c; Scott et al. 2004; Zaichkina et al. 2004;
Elmore et al. 2005; Ina and Sakai 2005; Tubiana 2005; Tubiana et al. 2005;
Boreham et al. 2006; Mothersill and Seymour 2006; Redpath 2006;
Pollycove 2007; Portess et al. 2007; Sanders and Scott 2007; Scott and Di
Palma 2007; Scott et al. 2007). For an extensive listing of the many early
radiation-associated hormesis publications, see Dr. Luckey’s (1991) book
entitled Radiation Hormesis. 
The indicated radiation-associated hormesis publications and others
collectively demonstrate that low doses/dose rates of low-LET radiation:
New low-dose-radiation risk assessment paradigm
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• Activate protective apoptosis signaling pathways and stimulate immunity.
• Protect against spontaneous chromosomal damage, mutations, neo-
plastic transformation, and cancer.
• Protect against high dose chemical- and radiation-induced cancer.
In spite of these now widely published hormetic effects, regulatory
agencies still use the LNT-based system for regulating human exposure to
ionizing radiation and for low-dose cancer risk estimation. Use of the
LNT-based system is considered justifiable by many outside the hormesis
community in light of publications such as the BEIR VII Report (NRC
2006), published by the U.S. National Research Council/National
Academy of Science. The BEIR VII report concluded that the LNT
approach to low-dose risk assessment was valid and essentially dismissed
radiation-associated hormesis. A corresponding French Academies
report did not come to the same conclusions (Tubiana 2005; Tubiana et
al. 2005) when examining essentially the same data that were reviewed in
the BEIR VII report. The French report found hormesis to be plausible
and the LNT risk function to be invalid for low-LET radiation doses < 100
mGy and especially for doses < 10 mGy.
In the next section, three epidemiological tricks are discussed that when
used helps to justify continued use of the LNT framework for low-dose-radi-
ation risk assessment. An approach for accounting for radiation-associated
hormetic effects in regulating radiation exposure is then discussed.
EPIDEMIOLOGICAL TRICKS THAT FAVOR A LNT DOSE-RESPONSE
CURVE
Trick #1: Throwing Away Radiation Dose
With many previous epidemiological studies of radiation-induced can-
cer, the researchers somehow came to the conclusion that radiation dose
was wasted. Thus, in order to correct for the so-called wasted dose, one has
to lag (throw away) some of the dose. However, if the dose-response curve
is indeed of the LNT type, then each fixed infinitesimally small increment,
dD, in the radiation dose, D, would be expected to be associated with the
exact same increment in the cancer risk (i.e., risk per individual). Stated
mathematically, if R(D) is the dose-dependent LNT risk function and D is
the radiation dose and α is the slope of the LNT dose-response curve, then
the fixed increment in risk is dR(D) = αdD; each small increment dD in the
dose increases the risk by the amount αdD. Now there is a problem! If each
increment in dose is equally effective in increasing risk, how can one con-
clude that dose is wasted? One cannot in one breath claim the existence
of a LNT risk function, then in the next breath claim dose wasting and
throw away dose. It is wrong to simply throw away radiation dose in order
to obtain a LNT dose-response curve!
B. R. Scott
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When studying DNA double-strand break induction by radiation, one
usually observes a LNT-type dose-response curve at low doses (NRC
2006). This seems to be the basis for the expectation by many experts that
cancer risk is also a linear function of dose. Interestingly, no dose lagging
is used when evaluating DNA double-strand break dose-response curves;
possibly because the inappropriateness of doing so would be immediate-
ly realized by many if not most radiation researchers. 
To illustrate how radiation hormesis can be hidden by this dose lag-
ging trick, data are presented in Figure 1 for in vitro neoplastic transfor-
mation after brief high-rate exposure to gamma rays, based on studies of
Redpath et al. (2001). The cells used were HeLa x skin fibroblast, and rel-
ative risk (RR) for these cells has been demonstrated to agree quite well
with RR data for cancer (leukemia and solid tumors) induction in
humans after brief high-rate exposure (Redpath et al. 2001). Note the
hormetic zone between 0 and 100 mGy (which corresponds to the
hormetic zone demonstrated by Azzam et al. (1996) using x rays and
mouse embryo fibroblast cells) where RR is suppressed to < 1. Figure 2
shows the same data as in Figure 1 with doses lagged by 100 mGy. The
radiation hormesis has magically disappeared! There is no longer a
hormetic zone. This dose lagging trick is still widely used in epidemio-
logical studies but needs to be stopped. Publishers should no longer allow
this trick to be used to deceive the readers and funding agencies. Use of
the indicated trick contributed indirectly to the radiation phobia that led
to more than 100,000 misinformed physician-recommended abortions of
wanted births after the Chernobyl accident (Ketchum 1987). 
New low-dose-radiation risk assessment paradigm
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tion of HeLa x skin fibroblast human hybrid cells by brief high-rate exposure, based on in vitro data
from Redpath et al. (2001).
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Trick #2: Eliminating the Hormetic Zone via Averaging over Dose Groups
The second trick relates to forming dose groups comprised of per-
sons having received widely varying radiation doses (i.e., the minimum
and maximum doses [often reconstructed] for each dose group differs
greatly). Such dose groups are usually necessary in case-control studies
and are also often used in cohort studies of irradiated populations. Here
the focus is on case-control study design and the use of odds ratio (OR)
as an estimate of RR.
The neoplastic transformation frequency data used for the RR curve
presented in Figure 1 can also be converted to odds of neoplastic trans-
formation and the odds used to obtain OR relative to controls which are
point estimates (without grouping) as indicated in Figure 3. Note that the
hormetic zone is still present and that the dose-response curve is almost
identical to the curve in Figure 1. For low frequency stochastic biological
effects, OR and RR are quite similar. Dose groups were then formed over
the following intervals: 0 to 100 mGy, 101 to 300 mGy, 301 to 500 mGy,
and 501 to 1000 mGy. The odds for neoplastic transformation were then
averaged over these intervals. Then, these averages were used to calculate
OR relative to the lowest dose group, which corresponds to the averaging
carried out and methodologies employed in case-control studies of can-
cer induction. The results obtained are presented in Figure 4, with the
lowest dose group plotted at a dose of 0 (as is done in some epidemio-
logical studies) and the results for the other dose groups plotted at the
group midrange dose. Note that the hormetic zone has again disap-
peared. Thus, odds averaging over wide dose groups when evaluating OR
can also vanish the hormetic zone. Journal editors and the general pub-
lic need to be aware of this averaging trick when they are told that the
B. R. Scott
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from Redpath et al. (2001).
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dose-response data from case-control studies are consistent with the LNT
hypothesis, which implies that any amount of radiation is harmful no mat-
ter how small. Users of the odds averaging trick with no previous knowl-
edge of its hormetic zone vanishing capabilities should be more cautious
of how they interpret their research findings. 
Dose-grouping in cohort studies of radiation-induced cancer can also
vanish the hormetic zone when persons who received low doses are
included among the control group (representative of unexposed individ-
uals). This is because the study design has reduced power for demon-
strating suppressed risk at low doses when irradiated persons with radia-
tion doses in the hormetic zone are included in the control group (used
to represent unirradiated persons). 
New low-dose-radiation risk assessment paradigm
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FIGURE 3. Odds ratio relative to controls for the neoplastic transformation data presented in Figure
1 for gamma-ray exposure of HeLa x skin fibroblast human hybrid cells.
FIGURE 4. Ratio of dose-interval-specific average odds for neoplastic transformation based on data
in Figure 3. Ratio of average odds evaluated relative to the lowest dose group. The lowest dose group
was plotted at dose = 0 mGy. Other data plotted at the midrange of the dose intervals are used.
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Trick #3: Constraining the Slope of the Cancer Risk Dose-response Curve
to Always Be Positive 
A trick often employed in cohort and case-control studies is to con-
strain the slope of the dose-response curve to be positive while including
high-dose, high-risk data in the analysis of the dose-response curve fit. This
is especially true when a LNT function has been presumed to apply at low
doses by the researchers. Irrespective of the low-dose data, an increase in
risk is predicted as dose increases for all such studies. The conclusion that
any dose is harmful then follows. Low-dose hormetic (U- and J-shaped)
data departing from the LNT characteristic is often simply ignored. It is
wrong to portray such data as part of a LNT curve! Low-dose risk assess-
ments should account for the hormetic shape to the dose-response curve.
HORMESIS IMPLICATIONS FOR REGULATORY POLICY
In Zbigniew Jaworowski’s1997 article, Beneficial Effects of Radiation and
Regulatory Policy, he states the following:
Adaptive stimulating effects of ionizing radiation occur at near natu-
ral doses. This disagrees with linear, no-threshold hypothesis on the
dose/effect relationship, which is a basis of the current radiation pro-
tection. Vast literature demonstrates that such effects, usually known
as hormetic ones, occur at molecular, cellular and population levels,
and often result in increased longevity and decreased cancer inci-
dence. . . . After the Chernobyl accident, adverse health effects and
vast material losses were induced in the former USSR by practical
implementation of the ICRP radiation protection recommendations.
A revision of the current approach to managing the risk of ionizing
radiation is needed for the public interest.
Here, an approach to regulating radiation exposure is recommended
that allows for the existence of a hormetic dose zone just above natural
background radiation. The approach relates to the hormetic relative risk
(HRR) model previously developed by this author (Scott 2007 a,b,c),
which is summarized below in a more general form.
Hormetic Relative Risk Model
With the HRR model for low-dose radiation-induced cancer, doses at
or slightly above normal monthly natural background low-LET radiation
levels are presumed to fall within the what is currently considered the
hormetic zone. This hormetic zone starts at natural background radia-
tion and spans a relative wide dose range, possibly exceeding 1000 mGy
of low-LET radiation when radiation dose is delivered at a low rate.
However, protective effects associated with hormesis may also occur at
B. R. Scott
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below current natural background levels for some individuals. For low-
LET radiation doses in the hormetic zone, cancer RR from exposure to
low-LET radiation in excess of natural background is expected to remain
< 1 for most if not all members of the population. Also, for combined
exposure to low doses of low- and high-LET radiations above natural
background radiation levels, the low-LET component of the dose acti-
vates protective hormetic processes and prevents cancer RR from increas-
ing above 1. The risk may decrease as a result of hormetic processes that
are regulated by protective intercellular and intracellular signaling. 
The protective signaling, presumed activated with low doses and dose
rates of low-LET radiation, relates to removal of aberrant cells from the
body via p53-dependent and independent apoptosis signaling pathways
and stimulated immunity (Scott 2007 a,b,c; Scott and Di Palma 2007;
Scott et al. 2007). The protective signaling can also involve DNA repair
pathways if a damage threshold is exceeded (Rothkamm and Löbrich
2003). Possible exceptions to full hormetic protection are the very young
and children who may not have significant burdens of genomically unsta-
ble cells that participate in the signaling associated with protective p53-
independent apoptosis (Scott and Di Palma 2007). 
Stochastic thresholds (StoThresh) that vary between different indi-
viduals are required in the HRR model for activating the protective sig-
naling. However, somewhat higher doses (also StoThresh) inhibit protec-
tion causing an increase in the RR as dose increases up to a point at which
protection is suppressed in all individuals. At this point, a linear response
that extrapolates to RR = 1 at background radiation b is presumed to
apply (Figure 5). This corresponds to use of the LNT model to extrapo-
late from high to low doses.
The mathematical functions discussed in this paper relate to radia-
tion doses equal to or greater than natural background radiation. For this
dose range, the indicated nonlinear hormetic RR(D) function (popula-
tion average) can be evaluated as arising from a weighting between two
RR(D) function components: a LNT component (RRLNT) that applies to
unprotected individuals and a hormetic component (RRHORM) that
applies to protected individuals. The weighting function, PROTEC(D), is
the probability function for activated protection (radiation hormesis) as
a function of the dose vector, D (called a covariate dose vector by some),
which relates to all relevant radiation doses (from low- and high-LET
sources) in excess of natural background. PROTEC(D) represents the
proportion of the irradiated population that is protected via p53-inde-
pendent apoptosis and induced immunity and is expected to depend on
genetic and other characteristics of the population. The RR(D) for per-
sons with the same nonzero dose vector D, under this model is given by
RR(D) = PROTEC(D)RRHORM(D) + (1 – PROTEC(D))RRLNT(D). (1)
New low-dose-radiation risk assessment paradigm
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Equation 1 is used to characterize the population average RR and
applies to radiation doses in excess of natural background. Equations that
relate to below natural background radiation exposures are not
addressed in this paper. The function RRHORM(D) = 1 – PROFAC is for
doses in the hormetic zone and equals 1 otherwise (Scott 2007a). The
protection factor (PROFAC) gives the expected proportion of cancer
cases that are prevented due to radiation hormesis and only relates to the
low-LET component of the total radiation dose. The PROFAC relates both
to protective apoptosis (presumed p53-independent) and immune func-
tioning but does not relate to DNA repair (Scott 2007a). The function
RRLNT(D) simply adds to RR = 1 (with no radiation exposure) the sum
K ′D, where K ′ is a row vector of radiation-specific slope factors for excess
cancers for matching radiation-specific doses in the dose vector D (a col-
umn vector). For a single radiation type K ′D = kD, where k is the excess
RR per unit dose and D is the individual radiation dose. Components of
the vector K ′ depend on DNA repair capacity (Scott 2007a) which is
expected to be greatly reduced in below natural background radiation
environments (Rothkam and Löbrich 2003). Components of K ′ are
expected to increase as DNA repair capacity decreases, which is expected
to be the case for below natural background radiation exposure. For
B. R. Scott
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FIGURE 5. Schematic representation of the hormetic relative risk model. The model is presented as
a function of the total absorbed radiation dose D to allow for a two-dimensional representation. The
dose scale ranges from hypothetical absolute zero natural background radiation dose (D = 0) to doses
in excess of the current dose b from natural background. Doses D*, D** and D*** define the differ-
ent dose zones indicated. The RR at absolute zero radiation is indicated by RR*. The exponential rise
as dose decreases below b is supported by epidemiological data (Cohen 1995) for environmentally
irradiated humans and is presumed to relate to reduced DNA repair capacity (Rothkam and Löbrich
2003), the loss of protective apoptosis (Scott and Di Palma 2007), and the loss of stimulation of
immune functions (Liu et al. 1987).
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above natural background radiation exposures, components of K ′ are
currently modeled as being constant. 
For just above natural background radiation exposure PROTEC(D) is
evaluated presently as 1, decreasing only when one exits the hormetic
zone (through a transition zone) at moderate to high doses. For natural
background radiation exposure, RR(D) = 1. The RR dose-response curve
associated with Equation 1 when plotted as a function of the total radia-
tion dose (indicated by D in this example) has the general features as
indicated in Figure 5 for doses ≥ natural background b. The figure how-
ever presents doses ranging from absolute zero natural background radi-
ation exposure to doses considerably in excess of background radiation
exposure. 
What has traditionally been considered the hormetic zone comprises
the above natural background range of radiation doses for which RR < 1.
However, for doses below and above this zone, protective effects can be
operational for some individuals. With the HRR model, RR increases
above 1 to RR* as the radiation dose decreases below natural background
to absolute zero radiation, due to a progressive loss of protected individ-
uals. Over the dose range for which RR < RR*, the dose-response curve is
expected to have a U- or J-shape. The schematic exponential increase of
RR in Figure 5 as dose decreases below natural background b is support-
ed by data on human lung cancer mortality rates (Cohen 1995) and data
revealing a loss of essential DNA repair capacity in low-dose radiation
environments (Rothkamm and Löbrich 2003).
Transition Zone A in Figure 5 is where StoThresh for activating pro-
tective signaling are progressively exceeded as radiation dose increases.
When protective signaling is activated in all members of the population,
then the RR is roughly constant through what is called the Zone of
Maximal Protection. At doses just above this zone, StoThresh for inhibit-
ing protective signaling (immune system stimulation, protective p53-inde-
pendent apoptosis, but not p53-related DNA repair) are progressively
exceeded as dose increases (Transition Zone B). At somewhat higher
doses, protection is suppressed in everyone (except for p53-related DNA
repair) and what is called here the Linear Zone then emerges. This zone
was previously called the LNT Zone because of intersection of a LNT line
(Scott and Di Palma 2007), but this proved to be confusing terminology.
The Linear Zone corresponds to the dose region where most epidemio-
logical studies have mainly been conducted that claimed a LNT dose-
response curve. For this zone, PROTEC(D) = 0, so that RR(D) = RRLNT(D).
For very high doses, departure from linearity can again emerge due to
lethal damage to body organs such as the bone marrow.
Over Transition Zone A, PROTEC(D) increases from zero to 1 and
remains at 1 over the Zone of Maximal Protection. Over Transition Zone
B, PROTEC(D) decreases from 1 to 0. 
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Regulatory Threshold with Respect to Cancer Induction
It is beneficial to define a regulatory radiation absorbed dose thresh-
old (REGRADT) based on the StoThresh, Tj,i , for loss of protection
against cancer in tissue, j, due to dose from the i th radiation type of inter-
est. The indicated REGRADT can be assigned as the radiation-specific
dose that corresponds to the minimum individual dose for transitioning
from the Zone of Maximal Protection to Zone B. Let Tj,i{min} represent
the tissue-j-specific minimum absorbed dose from radiation of the i th
radiation type (e.g., x rays, gamma rays, electrons, positrons, protons,
muons, neutrons, alpha particles, fission fragments, nonrelativistic heavy
nuclei, etc.), for Zone B. The REGRADT is therefore determined by the
most sensitive member of the population, related to loss of protection
over Transition Zone B. The REGRADT therefore likely depends on the
types of radiation involved, dose rates, radiation energies, the population
at risk, and the tissue of interest. The dose D** in Figure 5 corresponds
to the proposed REGRADT. Higher doses produce harm in part via loss
of hormetic protection.
One can then use the normalized stochastic effect dose, Sj , for tissue
j as defined below to limit radiation-induced cancers (with respect to pre-
venting excess cancers relative to the spontaneous frequency):
Sj = (Dj,1/Tj,1{min}) + (Dj,2/Tj,2{min}) + . . . + (Dj,n/Tj,n{min}) < 1, (2)
for all tissues j and all n radiations of interest. A value Sj = 0.5 means that
only one half of the require radiation exposure for loss of adaptive pro-
tection by the most sensitive member of the population has occurred.
This example does not account for genetic effects. However, it is wide-
ly known that genetic effects are much less likely to be induced than can-
cer (NRC 2006). Thus, limiting testicular and ovarian cancer occurrence
would be expected to also limit genetic effects. There is also some evi-
dence for dose-response relationships for genetic effects in humans being
of the hormetic type with respect to low-rate exposure to gamma rays
(Chen et al. 2007). Limiting both cancer and genetic effect occurrences
would be expected to also limit shortening of life due to deleterious
genetic effects and cancer.
The REGRADT as defined would apply both to population and indi-
vidual exposures. New, funded research is needed in order to properly
assign appropriate values for Tj,i{min} for different radiations, radiation
energies (e.g., neutron energy), different cancer types, and for different
populations.
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CONCLUSIONS
There is abundant evidence for radiation-associated hormesis.
However, dismissal of radiation-associated hormesis is in many instances
based on epidemiological tricks that include dose lagging, odds averaging
over wide dose ranges when evaluating OR, and forcing a positive slope to
the RR dose-response curve.
Its time for new, low-dose radiation risk assessment and regulatory
paradigms that allow for hormesis. Normalized stochastic effects dose,
based on radiation-, radiation-energy-, and dose-rate-specific REGRADTs
could be used to limit radiation exposure. For Sj limited to < 1, for all tis-
sues, cancer RR ≤ 1 would be expected.
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